- The top 10 best selling drugs in 2018 generated $90 billion in revenues for large pharma companies
- This comes at a time when many of the top drug makers are facing pressures about drug pricing
AbbVie’s (NYSE:ABBV) arthritis drug Humira remains the best selling drug in the world with over $20B in sales, more than double the second place Eliquis.
Combined, the top 10 best selling drugs in 2018 generated over $90B in revenues. Many of the drug developers, including Bristol-Myers Squibb (NYSE:BMY) and Merck (NYSE:MRK) are facing scrutiny for pricing drugs north of $100,000/year in the USA when in other countries the same drugs sell for a fraction of the costs.
Article by: Mick Ross
Mick is currently a full-time investor and formerly a buy-side analyst (2yrs) covering healthcare companies. Before that, he was a salesperson at a bulge-bracket firm, based in Dallas, Texas. Mick blogs to clarify and synthesize his investment thought process and to elicit feedback; additionally he likes to connect with other investors and swap ideas.